# Psychiatry (OCD) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN-TD
- Date: 1947-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Leonor Bachmann-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Anselm Garrity-Moyo, MD

## Reason for consultation

Contamination fears with washing and avoidance rituals taking about four hours a day in a 41-year-old aviator and businessman, ten months after a near-fatal plane crash, who has chronic pain and an opioid use disorder on prescribed codeine. Please confirm the diagnosis and advise on medication, exposure and response prevention, and the part his household staff play in his rituals. **S**

## History

Mr. Hughes, a 41-year-old aviator and aircraft builder, is seen at the request of Dr. Garrity-Moyo one week after intake. He describes a fear for his health since boyhood and, for about a year, fears of contamination that became much worse after the crash ten months ago: unwanted thoughts that he will be contaminated from outside, by people, door handles, money and food, with washing, cleaning and avoidance that take about four hours a day. He knows the fears are out of proportion but cannot resist the rituals. He does not feel that things must be done in a perfect order for their own sake, he has no fixed belief that he has a serious illness, and he has no nightmares or flashbacks of the crash, though he avoids talking about it. He has no hallucinations and no beliefs that others are harming him. His staff wash before handing him anything, pass him objects wrapped in tissue and screen visitors for illness. He wants treatment and wants it kept private. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert, restless and yawning about 20 hours after his last codeine dose; blood pressure 124/80, pulse 88 |
| Skin | Hands red and cracked from washing |
| Psychiatric | Anxious and courteous; contamination obsessions with washing and avoidance; insight good to fair; no psychotic features; no suicidal or homicidal ideation |

BP 124/80 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 72.3 kg; BMI 19.8 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Garrity-Moyo's intake note and safety assessment. Y-BOCS 28. PCL-5 18 today. PHQ-9 9, GAD-7 12, DAST-10 5, AUDIT-C 1, PEG 6.7. Blood count, sodium 139 mmol/L, potassium, creatinine 0.94 mg/dL, eGFR 104, liver enzymes, TSH 1.6 and urine albumin normal; albumin 3.7 g/dL. Urine drug test positive for codeine and morphine only. Prescription monitoring report: codeine from two prescribers. Buprenorphine starts today. PCL-5: 18. All results are synthetic.

## Assessment

1. **Obsessive-compulsive disorder, contamination type, with good or fair insight** (F42.2). The DSM-5-TR criteria are met: intrusive, unwanted contamination obsessions and washing, cleaning and avoidance compulsions aimed at preventing harm, taking more than an hour a day and limiting his work. He recognizes the fears are probably excessive, so the specifier is with good or fair insight; there is no tic history. The rituals are distressing to him, which separates this from obsessive-compulsive personality disorder; his fear is of contamination rather than of having an illness, which separates it from illness anxiety disorder; the PCL-5 of 18 and the absence of re-experiencing argue against post-traumatic stress disorder; and there are no psychotic features. Y-BOCS 28 is in the severe range. **S**
2. **Medication**. An SSRI at OCD doses with exposure and response prevention is first-line under the APA guideline and NICE CG31. Sertraline is preferred to fluvoxamine, which inhibits the enzymes that clear buprenorphine. Start at 50 mg and raise every four to six weeks as tolerated toward 200 mg; OCD often needs higher doses and longer trials than depression, and a fair trial is 8 to 12 weeks with at least four to six weeks at the highest tolerated dose. Check tolerability two weeks after each change and the sodium at follow-up. **S**
3. **Exposure and response prevention**. Exposure and response prevention is the psychological treatment with the best evidence. A hierarchy built with him, from door handles and shared objects to food made by others, restaurants, handshakes and finally the clinic bathroom, with weekly 90-minute sessions and daily home practice, moving to twice weekly once he is engaged. Sessions can be held at the clinic early in the day to protect his privacy. **S**
4. **Household staff**. His staff are doing what family members often do: carrying out rituals and giving reassurance, which keeps the fears going. Money and staff remove every natural limit on avoidance. With his written consent, his assistant should join two sessions to learn to step back in planned stages that follow his hierarchy and to offer support instead of reassurance. Staff should not be asked to monitor or report on him. **S**
5. **If the response is poor**. If the Y-BOCS has fallen by less than about 25 to 35 percent after 8 to 12 weeks at the highest tolerated sertraline dose with good exposure therapy, add a low-dose antipsychotic (aripiprazole or risperidone) or switch to clomipramine, with an ECG first. Neither is needed now. **S**
6. **Opioid use disorder and safety** (F11.20). Buprenorphine treats the opioid use disorder and helps his pain, and it has no important interaction with sertraline. He has no suicidal ideation; the safety plan, naloxone and weekly dispensing are appropriate. Review suicidal thoughts at each visit, as SSRIs can briefly increase restlessness early on. **S**

## Recommendations

1. Start sertraline 50 mg daily; raise to 100 mg after about four weeks and toward 200 mg after a further four to six weeks if tolerated, with a check two weeks after each change and a sodium level at follow-up.
2. Exposure and response prevention with the clinic psychologist, weekly 90-minute sessions with daily home practice, then twice weekly.
3. With his written consent, his assistant joins two sessions; staff stop carrying out rituals in planned steps and offer support instead of reassurance; staff are never asked to report on him.
4. Rate the Y-BOCS at every visit.
5. If the response is poor after 8 to 12 weeks at the highest tolerated dose, add aripiprazole or risperidone at a low dose or switch to clomipramine after an ECG.
6. Build meals and food made by others into the exposure hierarchy, with a dietitian.
7. Continue the safety plan, naloxone and the 988 Suicide & Crisis Lifeline, with safety reviewed at every visit.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Garrity-Moyo, who saw him the same day. The diagnosis and options were explained to Mr. Hughes in plain words; he chose to start sertraline and exposure therapy and signed consent for his assistant to join two sessions. **S**

## Follow-up

Dr. Garrity-Moyo continues the visits and prescribing, and the clinic psychologist provides the exposure therapy; psychiatry will see him again if the Y-BOCS has not fallen by at least 25 percent after 12 weeks at the highest tolerated dose, or for any new suicidal thoughts. **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association (American Journal of Psychiatry 2007;164(7 Suppl):5-53)
- Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2022;71(3):1-95)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
